DYRK1A suppression attenuates HIF1α accumulation and enhances the antiliver cancer effects of regorafenib and sorafenib under hypoxic conditions.
Int J Oncol
; 60(4)2022 Apr.
Article
in En
| MEDLINE
| ID: mdl-35244188
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Phenylurea Compounds
/
Pyridines
/
Protein-Tyrosine Kinases
/
Protein Serine-Threonine Kinases
/
Hypoxia-Inducible Factor 1, alpha Subunit
/
Sorafenib
/
Liver Neoplasms
/
Hypoxia
Limits:
Humans
Language:
En
Journal:
Int J Oncol
Journal subject:
NEOPLASIAS
Year:
2022
Document type:
Article